RT Journal Article
SR Electronic
T1 Predictive Factors for Response to Abiraterone in Metastatic Castration Refractory Prostate Cancer
JF Anticancer Research
JO Anticancer Res
FD International Institute of Anticancer Research
SP 1057
OP 1063
VO 35
IS 2
A1 MEHRAN AFSHAR
A1 FAWAZ AL-ALLOOSH
A1 SARAH PIRRIE
A1 CLARE ROWAN
A1 NICHOLAS D. JAMES
A1 EMILIO PORFIRI
YR 2015
UL http://ar.iiarjournals.org/content/35/2/1057.abstract
AB Background: Management of metastatic castration refractory prostate cancer (CRPC) is rapidly evolving. Rationalisation of treatment requires identification of those patients more likely to benefit from a particular therapy. We reviewed the outcome of patients treated with abiraterone at our Institution to describe factors predictive for response. Patients and Methods: Patients with CRCP treated with abiraterone were identified. Baseline variables and potential prognostic factors were extracted from electronic records. Outcome measures included overall survival (OS), prostate-specific antigen (PSA) response and time to PSA progression (TTPP). The Kaplan–Meier method and Cox proportional hazards model were used to analyze survival data. Results: A total of 61 patients met the inclusion criteria. In multivariate analysis, three independent predictors of OS were identified: Duration of response to androgen deprivation therapy (ADT) (hazard ratio(HR)=0.95, p=0.006), performance status (HR=7.4, p=0.013), and baseline haemoglobin (HR=0.47, p≤0.001). Conclusion: This study has identified three factors predictive for response to abiraterone in CRPC. Duration of response to ADT has not been previously shown to be a predictive factor for patients with CRCP. We suggest that a prospective validation is required.